AI-Designed TB treatment could boost cure rates and cut side effects
NCT ID NCT07467252
First seen Apr 14, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests a new two-drug combination for tuberculosis (TB) designed by artificial intelligence. The goal is to see if it works better and causes fewer liver problems than the standard four-drug regimen. About 200 adults with newly diagnosed, drug-sensitive TB will take either the AI-optimized combo or standard treatment for 6 months, with 6 more months of follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Riyadh First Health Cluster, Ministry of Health
Riyadh, Riyadh Region, 11176, Saudi Arabia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.